Drug Profile
AZD 2207
Alternative Names: AZD2207Latest Information Update: 27 Feb 2009
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 29 Jan 2009 Discontinued - Phase-II for Obesity in Europe (unspecified route)
- 29 Jan 2009 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (unspecified route)
- 02 Feb 2007 Phase-I clinical trials in Obesity in Europe (unspecified route)